MGS0039: A potent and selective group II metabotropic glutamate receptor antagonist with antidepressant-like activity

Neuropharmacology

Volumn 46, Issue 4, 2004, Pages 457-467

  Chaki, Shigeyuki ^a   Yoshikawa, Ryoko ^a   Hirota, Shiho ^a   Shimazaki, Toshiharu ^a   Maeda, Maoko ^a   Kawashima, Naoya ^a   Yoshimizu, Takao ^a   Yasuhara, Akito ^a   Sakagami, Kazunari ^a   Okuyama, Shigeru ^a   Nakanishi, Shigetada ^b   Nakazato, Atsuro ^a  

^a TAISHO PHARMACEUTICAL CO LTD   (Japan)

^b KYOTO UNIVERSITY   (Japan)

Author keywords

Antidepressant; Depression; Group II metabotropic glutamate receptor; LY341495; mGluR; MGS0039

Indexed keywords

2 AMINO 2 (2 CARBOXYCYCLOPROPYL) 3 (XANTHEN 9 YL)PROPIONIC ACID; 2 AMINO 3 (3,4 DICHLOROBENZYLOXY) 6 FLUOROBICYCLO[3.1.0]HEXANE 2,6 DICARBOXYLIC ACID; ANTIDEPRESSANT AGENT; CYCLIC AMP; FORSKOLIN; GLUTAMATE RECEPTOR; GLUTAMATE RECEPTOR 2; GLUTAMATE RECEPTOR 3; GLUTAMIC ACID; GUANOSINE 5' O (3 THIOTRIPHOSPHATE); METABOTROPIC RECEPTOR ANTAGONIST; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CHO CELL; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; DRUG POTENCY; DRUG SYNTHESIS; FORCED SWIMMING TEST; IC 50; MALE; MAZE TEST; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RECEPTOR AFFINITY; RECEPTOR BINDING; SOCIAL INTERACTION;

EID: 10744233803     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2003.10.009     Document Type: Article

References (41)

1. Bai F., Bergeron M., Nelson D.L.G. Chronic AMPA receptor potentiator (LY451646) treatment increases cell proliferation in adult rat hippocampus. Neuropharmacology. 44:2003;1013-1021.
2. Bai F., Li X., Clay M., Lindstrom T., Skolnick P. Intra- and interstrain differences in models of "behavioral despair" Pharmacology Biochemistry and Behavior. 70:2001;187-192.
3. Battaglia G., Monn J.A., Schoepp D.D. In vivo inhibition of veratridine-evoked release of striatal excitatory amino acids by the group II metabotropic glutamate receptor agonist LY354740 in rats. Neuroscience Letters. 229:1997;161-164.
4. Borsini F., Podhorna J., Marazziti D. Do animal models of anxiety predict anxiolytic-like effects of antidepressants? Psychopharmacology. 163:2002;121-141.
5. Cartmell J., Monn J.A., Schoepp D.D. Attenuation of specific PCP-evoked behaviors by the potent mGluR2/3 receptor agonist, LY379268 and comparison with the atypical antipsychotic, clozapine. Psychopharmacology. 148:2000;423-429.
6. Chaki S., Hirota S., Funakoshi T., Suzuki Y., Suetake S., Okubo T., Ishii T., Nakazato A., Okuyama S. Anxiolytic-like and antidepressant-like activities of MCL0129 (1-[(S)-2-(4-fluorophenyl)-2-(4-isopropylpiperadin-1-yl) ethyl]-4-[4 - (2-methoxynaphthalen-1-yl)butyl]piperazine), a novel and potent nonpeptide antagonist of the melanocortin-4 receptor. Journal of Pharmacology and Experimental Therapeutics. 304:2003;818-826.
7. Conn P.J., Pin J.P. Pharmacology and functions of metabotropic glutamate receptors. Annual Review of Pharmacology & Toxicology. 37:1997;205-237.
8. Cryan J.F., Hoyer D., Markou A. Withdrawal from chronic amphetamine induces depressive-like behavioral effects in rodents. Biological Psychiatry. 54:2003;49-58.
9. Cryan J.F., Kelly P.H., Neijt H.C., Sansig G., Flor P.J., van Der Putten H. Antidepressant and anxiolytic-like effects in mice lacking the group III metabotropic glutamate receptor mGluR7. European Journal of Neuroscience. 17:2003;2409-2417.
10. Cryan J.F., Markou A., Lucki I. Assessing antidepressant activity in rodents: recent developments and future needs. Trends in Pharmacological Sciences. 23:2002;238-245.
11. Detke M.J., Rickels M., Lucki I. Active behaviors in the rat forced swimming test differentially produced by serotonergic and noradrenergic antidepressants. Psychopharmacology. 121:1995;66-72.
12. Danysz W., Parsons C.G., Bresink I., Quack G. Glutamate in CNS disorders. Drug News and Perspectives. 8:1995;261-277.
13. Duman R.S., Malberg J., Nakagawa S., D'Sa C. Neuronal plasticity and survival in mood disorders. Biological Psychiatry. 48:2000;732-739.
14. 50) following the detection of antagonism observed in the presence of intrinsic activity. Neuropharmacology. 38:1999;361-373.
15. Grillon C., Cordova J., Levine L.R., Morgan C.A. 3rd. Anxiolytic effects of a novel group II metabotropic glutamate receptor agonist (LY354740) in the fear-potentiated startle paradigm in humans. Psychopharmacology. 168:2003;446-454.
16. Harrison A.A., Liem Y.T.B., Markou A. Fluoxetine combined with a serotonin-1A receptor antagonist reversed reward deficits observed during nicotine and amphetamine withdrawal in rats. Neuropsychopharmacology. 25:2001;55-71.
17. Helton D.R., Tizzano J.P., Monn J.A., Shoepp D.D., Kallman M.J. Anxiolytic and side-effect profile of LY354740: a potent, highly selective, orally active agonist for group II metabotropic glutamate receptors. Journal of Pharmacology and Experimental Therapeutics. 284:1998;651-660.
18. 3H]-LY341495 as a novel antagonist radioligand for group II metabotropic glutamate (mGlu) receptors: characterization of binding to membranes of mGlu receptor subtype expressing cells. Neuropharmacology. 38:1999;1519-1529.
19. Kenny P.J., Gasparini F., Markou A. Group II metabotropic and AMPA/kainate glutamate receptors regulate the deficit in brain reward function associated with nicotine withdrawal in rats. Journal of Pharmacology and Experimental Therapeutics. 306:2003;1068-1076.
20. Li X., Tizzano J.P., Griffey K., Clay M., Lindstrom T., Skolnick P. Antidepressant-like actions of an AMPA receptor potentiator (LY392098). Neuropharmacology. 40:2001;1028-1033.
21. Lorrain D.S., Baccei C.S., Bristow L., Anderson J.J., Varney M.A. Effects of ketamine and N-methyl-D-aspartate on glutamate and dopamine release in the rat prefrontal cortex: modulation by a group II selective metabotropic glutamate receptor agonist LY379268. Neuroscience. 117:2003;697-706.
22. Mackowiak M., O'Neill M.J., Hicks C.A., Bleakman D., Skolnick P. An AMPA receptor potentiator modulates hippocampal expression of BDNF: an in vivo study. Neuropharmacology. 43:2002;1-10.
23. Markou A., Kosten T.R., Koob G.F. Neurobiological similarities in depression and drug dependence: a self medication hypothesis. Neuropsychopharmacology. 18:1998;135-174.
24. Matrisciano F., Storto M., Ngomba R.T., Cappuccio I., Caricasole A., Scaccianoce S., Riozzi B., Melchiorri D., Nicoletti F. Imipramine treatment up-regulates the expression and function of mGluR2/3 metabotropic glutamate receptors in the rat hippocampus. Neuropharmacology. 42:2002;1008-1015.
25. Meldrum B.S. Glutamate as a neurotransmitter in the brain: review of physiology and pathology. Journal of Nutrition. 130:2000;1007S-1015S.
26. Monn J.A., Valli M.J., Massey S.M., Wright R.A., Salhoff C.R., Johnson B.G., Howe T., Alt C.A., Rhodes G.A., Robey R.L., Griffey K.R., Tizzano J.P., Kallman M.J., Helton D.R., Schoepp D.D. Design, synthesis, and pharmacological characterization of (+)-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid (LY354740): a potent, selective, and orally active group 2 metabotropic glutamate receptor agonist possessing anticonvulsant and anxiolytic properties. Journal of Medicinal Chemistry. 40:1997;528-537.
27. Moreau J.L., Scherschlicht R., Jenck F., Martin J.R. Chronic mild stress-induced anhedonia model of depression; sleep abnormalities and curative effects of electroshock treatment. Behavioral Pharmacology. 6:1995;682-687.
28. Nakanishi S. Molecular diversity of glutamate receptors and implications for brain function. Science. 258:1992;597-603.
29. Nakanishi S. Metabotropic glutamate receptors: synaptic transmission, modulation, and plasticity. Neuron. 13:1994;1031-1037.
30. Nakanishi S., Masu M. Molecular diversity and functions of glutamate receptors. Annual Review of Biophysics and Biomolecular Structure. 23:1994;319-348.
31. Nakazato A., Kumagai T., Sakagami K., Yoshikawa R., Suzuki Y., Chaki S., Ito H., Taguchi T., Nakanishi S., Okuyama S. Synthesis, SARs, and pharmacological characterization of 2-amino-3 or 6-fluorobicyclo[3.1.0]hexane-2, 6-dicarboxylic acid derivatives as potent, selective, and orally active group II metabotropic glutamate receptor agonists. Journal of Medicinal Chemistry. 43:2000;4893-4909.
32. Ohnishi H., Shigemoto R., Nakanishi S., Mizuno N. Distribution of the messenger RNA for a metabotropic glutamate receptor, mGluR2, in the central nervous system of the rat. Neuroscience. 53:1993;1009-1018.
33. Ohnishi H., Shigemoto R., Nakanishi S., Mizuno N. Distribution of the mRNA for a metabotropic glutamate receptor (mGluR3) in the rat brain: an in situ hybridization study. Journal of Comparative Neurology. 335:1993;252-266.
34. Pilc A., Legutko B. The influence of prolonged antidepressant treatment on the changes in cyclic AMP accumulation induced by excitatory amino acids in rat cerebral cortical slices. Neuroreport. 29:1995;85-88.
35. Pin J.P., Duvoisin R. The metabotropic glutamate receptors: structure and functions. Journal of Neurochemistry. 58:1992;1184-1186.
36. Porsolt R.D., Lenegre A. Behavioural models of depression. Elliott J., Heal D.J., Marsden C.A. Experimental approaches to anxiety and depression. 1992;73-85 John Wiley and Sons, London.
37. Schoepp D.D. Novel functions for subtypes of metabotropic glutamate receptor. Neurochemistry International. 24:1994;13-20.
38. Schoepp D.D., Conn P.J. Metabotropic glutamate receptors in brain function and pathology. Trends in Pharmacological Sciences. 14:1993;13-20.
39. Shirayama Y., Chen A.C.H., Nakagawa S., Russell D.S., Duman R.S. Brain-derived neurotrophic factor produces antidepressant effects in behavioral models of depression. Journal of Neuroscience. 22:2002;3251-3261.
40. Steru L., Chermat R., Thierry B., Simon P. The tail suspension test: a new method for screening antidepressants in mice. Psychopharmacology. 85:1985;367-370.
41. 3H]LY341495) to cell membranes expressing recombinant human group III metabotropic glutamate receptor subtypes. Naunyn-Schmiedeberg's Archives of Pharmacology. 362:2000;546-554.